Deakin University
Browse

File(s) under permanent embargo

A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: a double-blind randomized controlled trial

Version 2 2024-06-02, 13:18
Version 1 2015-03-17, 15:43
journal contribution
posted on 2024-06-02, 13:18 authored by Michael BerkMichael Berk, S Brook, AI Trandafir
Little controlled data exist on the treatment of substance induced psychotic disorders. In this study, 30 patients meeting DSM-IV criteria for cannabis induced psychotic disorder were randomly allocated to receive either olanzapine or haloperidol in a 4-week double-blind clinical trial. There were no significant outcome differences between the two groups on any of the primary outcome measures, the Brief Psychiatric Rating Scale (haloperidol 25.7; olanzapine 27.1; P = 0.70); Clinical Global Impression (CGI) severity scale (haloperidol 1.8, olanzapine 2.3; P = 0.21) or the CGI improvement scale (haloperidol 1.3, olanzapine 1.7; P = 0.16). The haloperidol group however, developed significantly more extrapyramidal side-effects as measured by the Simpson Angus Scale (haloperidol 11.4, olanzapine 2.5; P = 0.014). Significantly (P = 0.027) more biperidin was used for extrapyramidal side-effects in the haloperidol (7.143 mg) than in the olanzapine (0.357 mg) group. Olanzapine appears to be as effective as haloperidol in the treatment of cannabis induced psychotic disorder, but is associated with a lower rate of extrapyramidal side-effects.

History

Journal

International clinical psychopharmacology

Volume

14

Pagination

177-180

Location

London, Eng.

ISSN

0268-1315

eISSN

1473-5857

Language

eng

Publication classification

C1.1 Refereed article in a scholarly journal

Copyright notice

1999, Lippincott Williams & Wilkins

Issue

3

Publisher

Lippincott Williams & Wilkins